# EDGAR Filing Document

**Accession Number:** 0001217234
**File Stem:** 0001217234-26-000007
**Filing Date:** 2026-1
**Character Count:** 10788
**Document Hash:** b7715cd5323e029f8dcafa13b29e6053
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001217234-26-000007.hdr.sgml**: 20260112

**ACCESSION NUMBER**: 0001217234-26-000007

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 14

**CONFORMED PERIOD OF REPORT**: 20260112

**ITEM INFORMATION**: Results of Operations and Financial Condition

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20260112

**DATE AS OF CHANGE**: 20260112

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** CareDx, Inc.
- **CENTRAL INDEX KEY:** 0001217234
- **STANDARD INDUSTRIAL CLASSIFICATION:** SERVICES-MEDICAL LABORATORIES [8071]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 943316839
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-36536
- **FILM NUMBER:** 26524641

**BUSINESS ADDRESS:**
- **STREET 1:** 8000 MARINA BLVD
- **STREET 2:** 4TH FLOOR
- **CITY:** BRISBANE
- **STATE:** CA
- **ZIP:** 94005
- **BUSINESS PHONE:** 415-287-2300

**MAIL ADDRESS:**
- **STREET 1:** 8000 MARINA BLVD
- **STREET 2:** 4TH FLOOR
- **CITY:** BRISBANE
- **STATE:** CA
- **ZIP:** 94005

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** XDx, Inc.
- **DATE OF NAME CHANGE:** 20071010

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** EXPRESSION DIAGNOSTICS INC
- **DATE OF NAME CHANGE:** 20030203

?xml version='1.0' encoding='ASCII'? cdna-20260112

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION** 

**Washington, D.C. 20549** 

**FORM 8-K**

**CURRENT REPORT** 

**PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934** 

**Date of Report (Date of earliest event reported): January 12, 2026** 

**CAREDX, INC.** 

**(Exact Name of Registrant as Specified in its Charter)** 

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-36536** | **94-3316839** |
| **(State or Other Jurisdiction**<br>**of Incorporation)** | **(Commission**<br>**File Number)** | **(IRS Employer**<br>**Identification No.)** |

---

**8000 Marina Boulevard, 4th Floor**

**Brisbane, California 94005** 

**(Address of Principal Executive Offices) (Zip Code)** 

**(415) 287-2300** 

**Registrant's telephone number, including area code** 

**N/A** 

**(Former Name, or Former Address, if Changed Since Last Report)** 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Exchange Act:

---

| | | |
|:---|:---|:---|
| **(Title of each class)** | **(Trading Symbol)** | **(Name of exchange on which registered)** |
| **Common Stock, $0.001 Par Value** | **CDNA** | **The Nasdaq Stock Market LLC** |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

**Item 2.02 Results of Operations and Financial Condition.** 

On January 12, 2026, CareDx, Inc. (the "Company") issued a press release announcing its preliminary unaudited financial results for the quarter and year ended December 31, 2025. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

The information in this Item 2.02, including the press release attached hereto as Exhibit 99.1, is intended to be furnished under Item 2.02 and Item 9.01 of Form 8-K and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the "Securities Act"), or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

**Item 9.01. Financial Statements and Exhibits.** 

(d) Exhibits.

---

| | |
|:---|:---|
| **Exhibit No.** | **<u>Description</u>** |
| 99.1 | <u>[Press Release issued by CareDx, Inc., dated](jpm26pre-announcement11125.htm)[January](jpm26pre-announcement11125.htm)[12](jpm26pre-announcement11125.htm)[, 202](jpm26pre-announcement11125.htm)[6](jpm26pre-announcement11125.htm)[.](jpm26pre-announcement11125.htm)</u> |
| 104 | Cover Page Interactive Data File, formatted in Inline Extensible Business Reporting Language (iXBRL). |

---

------

**SIGNATURES** 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
| Date: January 12, 2026 | CAREDX, INC. |  |
|  | By: | /s/ JOHN W. HANNA |
|  |  | John W. Hanna |
|  |  | Chief Executive Officer |
|  |  | (Principal Executive Officer) |

---

## Exhibit 99.1

**Exhibit 99.1**

![logo.jpg](logo.jpg)

**CareDx Announces Preliminary Fourth Quarter and** 

**Full Year 2025 Financial Results**

*Expects Fourth Quarter Revenue Growth of Approximately 25% Year-Over-Year*

*Expects Full Year 2025 Revenue of Approximately $380 Million*

BRISBANE, Calif. — (BUSINESS WIRE)—January 12, 2025, CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today reported preliminary, unaudited financial results for the fourth quarter and full year 2025.

**Preliminary Fourth Quarter 2025 Financial Results**

&nbsp;&nbsp;&nbsp;&nbsp;• Revenue of approximately $108 million, an increase of 25% year-over-year

&nbsp;&nbsp;&nbsp;&nbsp;• Testing services revenue of approximately $78 million, an increase of 23% year-over-year

&nbsp;&nbsp;&nbsp;&nbsp;• Testing services volume of approximately 53,000, an increase of 17% year-over-year

&nbsp;&nbsp;&nbsp;&nbsp;• Average revenue per test of approximately $1,470 including approximately $5 million in prior period revenue

&nbsp;&nbsp;&nbsp;&nbsp;• Patient & digital solutions revenue of approximately $17 million, an increase of 47% year-over-year

&nbsp;&nbsp;&nbsp;&nbsp;• Product revenue of approximately $13 million, an increase of 17% year-over-year

&nbsp;&nbsp;&nbsp;&nbsp;• Share repurchase of $12 million during the quarter for 773,000 shares at an average price of $15.79 per share

**Preliminary Full Year 2025 Financial Results**

&nbsp;&nbsp;&nbsp;&nbsp;• Revenue of approximately $380 million, an increase of 14% year-over-year

&nbsp;&nbsp;&nbsp;&nbsp;• Testing services revenue of approximately $274 million, an increase of 10% year-over-year

&nbsp;&nbsp;&nbsp;&nbsp;• Testing services volume of approximately 200,000, an increase of 14% year-over-year

&nbsp;&nbsp;&nbsp;&nbsp;• Patient & digital solutions revenue of approximately $57 million, an increase of 31% year-over-year

&nbsp;&nbsp;&nbsp;&nbsp;• Product revenue of approximately $48 million, an increase of 19% year-over-year

&nbsp;&nbsp;&nbsp;&nbsp;• Cash, cash equivalents and marketable securities of approximately $200 million as of December 31, 2025

&nbsp;&nbsp;&nbsp;&nbsp;• Share repurchase of $88 million during the year for 5.8 million shares at an average price of $15.16 per share

------

"We had another quarter of strong testing services volume growth and record revenue across all segments of our business," said John W. Hanna, President and CEO. "Our solutions selling strategy is working. In 2026, we plan to build on this commercial momentum and advance our Transplant+ innovation pipeline."

The preliminary financial information presented in this press release is based on CareDx's current expectations and may be adjusted as a result of, among other things, the completion of customary annual audit procedures.

**About CareDx**

CareDx is a precision medicine company dedicated to improving outcomes for transplant patients and advancing organ health. The Company's integrated solutions include non-invasive molecular testing for heart, kidney, and lung transplants; laboratory products; digital health technologies; and patient solutions that support care before and after transplant. CareDx is the leading provider of genomics-based information for transplant patients. For more information, please visit www.caredx.com.

**Forward Looking Statements**

This press release includes forward-looking statements, including expectations regarding the achievement of CareDx's financial and operational goals and its expectations and prospects for 2025. These forward-looking statements are based upon information that is currently available to CareDx and its current expectations, speak only as of the date hereof, and are subject to numerous risks and uncertainties, all of which are difficult to predict and many of which are beyond CareDx's control, that could cause the actual results to differ materially from those projected, including general economic and market factors, and global economic and marketplace uncertainties, among others discussed in CareDx's filings with the Securities and Exchange Commission (the "SEC"), including, but not limited to, the Annual Report on Form 10-K for the fiscal year ended December 31, 2024 filed by CareDx with the SEC on February 28, 2025, and other reports that CareDx has filed with the SEC. Any of these may cause CareDx's actual results, performance, or achievements to differ materially and adversely from those anticipated or implied by CareDx's forward-looking statements. You are cautioned not to place undue reliance on these forward-looking statements. CareDx expressly disclaims any obligation, except as required by law, or undertaking to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.

**CareDx, Inc.**<br>Media

Natasha Moshirian Wagner<br>**<u>nwagner@CareDx.com</u>**

**Investors**<br> Caroline Corner

**<u>investor@CareDx.com</u>**

<br>